Kinase-likeness and kinase-privileged fragments: Toward virtual polypharmacology

Journal of Medicinal Chemistry

Volumn 51, Issue 5, 2008, Pages 1214-1222

  Aronov, Alex M ^a   McClain, Brian ^a   Moody, Cameron Stuver ^a   Murcko, Mark A ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEDIRANIB; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; PAZOPANIB; PHOSPHOTRANSFERASE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; SORAFENIB; SUNITINIB; VANDETANIB; VATALANIB;

ARTICLE; DRUG ACTIVITY; DRUG MARKETING; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME SPECIFICITY;

ANILINE COMPOUNDS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 41649105837     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701021b     Document Type: Article

References (42)

1. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science 2002, 298, 1912-1934.
2. Cohen, P. Protein kinases - The major drug targets of the twenty-first century. Nat. Rev. Drug Discovery 2002, 1, 309-315.
3. Lowrie, J. F.; Delisle, R. K.; Hobbs, D. W.; Diller, D. J. The different strategies for designing GPCR and kinase targeted libraries. Comb. Chem. High Throughput Screening 2004, 7, 495-510.
4. Klabunde, T.; Hessler, G. Drug design strategies for targeting G-protein-coupled receptors. ChemBioChem 2002, 3, 928-944.
5. Brunne, R. M.; Hessler, G.; Muegge, I. Virtual compound libraries and molecular modeling. Handbook of Combinatorial Chemistry. Drugs, Catalysts, Materials; Wiley-VCH: Weinheim, Germany, 2002; pp 761-783.
6. Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 1988, 31, 2235-2246.
7. Bemis, G. W.; Murcko, M. A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 1996, 39, 2887-2893.
8. Hajduk, P. J.; Bures, M.; Praestgaard, J.; Fesik, S. W. Privileged molecules for protein binding identified from NMR-based screening. J. Med. Chem. 2000, 43, 3443-3447.
9. Mason, J. S.; Morize, I.; Menard, P. R.; Cheney, D. L.; Hulme, C.; Labaudiniere, R. F. New 4-point pharmacophore method for molecular similarity and diversity applications: Overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. J. Med. Chem. 1999, 42, 3251-3264.
10. Schnur, D. M.; Hermsmeier, M. A.; Tebben, A. J. Are target-family- privileged substructures truly privileged? J. Med. Chem. 2006, 49, 2000-2009.
11. Muegge, I.; Enyedy, I. J. Virtual screening for kinase targets. Curr. Med. Chem. 2004, 11, 693-707.
12. Aronov, A. M.; Bemis, G. W. A minimalist approach to fragment-based ligand design using common rings and linkers: Application to kinase inhibitors. Proteins 2004, 57, 36-50.
13. Vieth, M.; Sutherland, J. J. Dependence of molecular properties on proteomic family for marketed oral drugs. J. Med. Chem. 2006, 49, 3451-3453.
14. Paolini, G. V.; Shapland, R. H.; van Hoorn, W. P.; Mason, J. S.; Hopkins, A. L. Global mapping of pharmacological space. Nat. Biotechnol. 2006, 24, 805-815.
15. Oshiro, C.; Bradley, E. K.; Eksterowicz, J.; Evensen, E.; Lamb, M. L.; Lanctot, J. K.; Putta, S.; Stanton, R.; Grootenhuis, P. D. Performance of 3D-database molecular docking studies into homology models. J. Med. Chem. 2004, 47, 764-767.
16. Manallack, D. T.; Pitt, W. R.; Gancia, E.; Montana, J. G.; Livingstone, D. J.; Ford, M. G.; Whitley, D. C. Selecting screening candidates for kinase and G protein-coupled receptor targets using neural networks. J. Chem. Inf. Comput. Sci. 2002, 42, 1256-1262.
17. Xia, X.; Maliski, E. G.; Gallant, P.; Rogers, D. Classification of kinase inhibitors using a Bayesian model. J. Med. Chem. 2004, 47, 4463-4470.
18. Briem, H.; Gunther, J. Classifying "kinase inhibitor-likeness" by using machine-learning methods. ChemBioChem 2005, 6, 558-566.
19. Ghose, A. K.; Crippen, G. M. Atomic physicochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships. I. Partition coefficients as a measure of hydrophobicity. J. Comput. Chem. 1986, 7, 565-577.
20. Muegge, I.; Heald, S. L.; Brittelli, D. Simple selection criteria for drug-like chemical matter. J. Med. Chem. 2001, 44, 1841-1846.
21. Dearden, J. C. In silico prediction of drug toxicity. J Comput.-Aided Mol. Des. 2003, 17, 119-127.
22. Greene, N.; Judson, P. N.; Langowski, J. J.; Marchant, C. A. Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. SAR QSAR Environ. Res. 1999, 10, 299-314.
23. Comprehensive Medicinal Chemistry (CMC-3D); MDL Information Systems, Inc.: San Leandro, CA, 1996.
24. Egan, W. J.; Walters, W. P.; Murcko, M. A. Guiding molecules towards drug-likeness. Curr. Opin. Drug Discovery Dev. 2002, 5, 540-549.
25. Aronov, A. M.; Murcko, M. A. Toward a pharmacophore for kinase frequent hitters. J. Med. Chem. 2004, 47, 5616-5619.
26. Cohen, P. The development and therapeutic potential of protein kinase inhibitors. Curr. Opin. Chem. Biol. 1999, 3, 459-465.
27. Drugbank. http://redpoll.pharmacy.ualberta.ca/drugbank/.
28. Feng, J. Vertex Pharmaceuticals, Inc., 2007, unpublished results.
29. Svetnik, V.; Liaw, A.; Tong, C.; Culberson, J. C.; Sheridan, R. P.; Feuston, B. P. Random forest: A classification and regression tool for compound classification and QSAR modeling. J. Chem. Inf. Comput. Sci. 2003, 43, 1947-1958.
30. Nilakantan, R.; Bauman, N.; Dixon, J. S.; Venkataraghavan, R. Topological torsions: A new molecular descriptor for SAR applications. Comparison with other descriptors. J. Chem. Inf. Comput. Sci. 1987, 27, 82-85.
31. Investigational Drugs Database. Thomson Scientific Ltd., Stamford, CT, 2006.
32. Doukas, J.; Wrasidlo, W.; Noronha, G.; Dneprovskaia, E.; Fine, R.; Weis, S.; Hood, J.; Demaria, A.; Soll, R.; Cheresh, D. Phosphoinositide 3-kinase γ/δ inhibition limits infarct size after myocardial ischemia/ reperfusion injury. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 19866-19871.
33. Arris, C. E.; Boyle, F. T.; Calvert, A. H.; Curtin, N. J.; Endicott, J. A.; Garman, E. F.; Gibson, A. E.; Golding, B. T.; Grant, S.; Griffin, R. J.; Jewsbury, P.; Johnson, L. N.; Lawrie, A. M.; Newell, D. R.; Noble, M. E.; Sausville, E. A.; Schultz, R.; Yu, W. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J. Med. Chem. 2000, 43, 2797-2804.
34. Davies, T. G.; Bentley, J.; Arris, C. E.; Boyle, F. T.; Curtin, N. J.; Endicott, J. A.; Gibson, A. E.; Golding, B. T.; Griffin, R. J.; Hardcastle, I. R.; Jewsbury, P.; Johnson, L. N.; Mesguiche, V.; Newell, D. R.; Noble, M. E.; Tucker, J. A.; Wang, L.; Whitfield, H. J. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat. Struct. Biol. 2002, 9, 745-749.
35. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
36. McInnes, C.; Fischer, P. M. Strategies for the design of potent and selective kinase inhibitors. Curr. Pharm. Des. 2005, 11, 1845-1863.
37. Kuo, G. H.; Wang, A.; Emanuel, S.; Deangelis, A.; Zhang, R.; Connolly, P. J.; Murray, W. V.; Graninger, R. H.; Sechler, J.; Fuentes-Pesquera, A.; Johnson, D.; Middleton, S. A.; Jolliffe, L.; Chen, X. Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors. J. Med. Chem. 2005, 48, 1886-1900.
38. Chakravarty, S.; Dugar, S. Alk5 (TGFβ R1) inhibitors: In vitro and in vivo characterization of novel orally active pteridines. Inhibitors of Protein Kinases; Polish Academy of Sciences (PAS): Warsaw, Poland, 2005.
39. Angell, R. M.; Atkinson, F. L.; Brown, M. J.; Chuang, T. T.; Christopher, J. A.; Cichy-Knight, M.; Dunn, A. K.; Hightower, K. E.; Malkakorpi, S.; Musgrave, J. R.; Neu, M.; Rowland, P.; Shea, R. L.; Smith, J. L.; Somers, D. O.; Thomas, S. A.; Thompson, G.; Wang, R. N-(3-Cyano-4,5,6,7-tetrahydro-1- benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg. Med. Chem. Lett. 2007, 17, 1296-1301.
40. Wermuth, C. G. Selective optimization of side activities: Another way for drug discovery. J. Med. Chem. 2004, 47, 1303-1314.
41. Siegel, M. G.; Vieth, M. Drugs in other drugs: A new look at drugs as fragments. Drug Discovery Today 2007, 12, 71-79.
42. Daylight Chemical Information Systems. http://www.daylight.com.